Impact of baseline characteristics on efficacy and safety after bortezomib-based induction and maintenance in newly diagnosed multiple myeloma (MM) patients ineligible for transplant in the phase IIIb UPFRONT study.


8072 Background: The multicenter, phase IIIb UPFRONT study compares the efficacy and safety of 3 bortezomib (Vc)-based induction regimens, VcD (Vc-dexamethasone), VcTD (Vc-thalidomide-dexamethasone) and VcMP (Vc-melphalan-prednisone), followed by weekly Vc maintenance, in newly diagnosed MM patients ineligible for HDT-SCT. METHODS Patients were randomized… (More)